Breyer Capital

Breyer Capital Research Overview Breyer Capital is an independent global venture capital and private equity firm founded by Jim Breyer in 2006, headquartered in Austin, Texas (since 2020) with an additional office in Menlo Park, California at 2180 Sand Hill Road. The firm is led by Jim Breyer, one of the most celebrated venture capitalists of his generation, known for early investments in Facebook (100x+ return), Etsy, Spotify, Marvel Entertainment, and Legendary. Breyer Capital maintains a highly selective, conviction-driven approach, making roughly 10 new investments per year across a multi-stage portfolio spanning seed through growth equity. The firm has backed 150+ companies, 15 unicorns, 10+ IPOs, and 21 acquisitions. Investment Thesis Breyer Capital's core thesis centers on "catalyzing high-impact entrepreneurs" with a deep conviction that artificial intelligence and machine learning will transform technology globally. Jim Breyer's guiding principle is "Never grow complacent: always commit to rapid improvement in technology and learning." The firm's stated belief is that "Technology is an enabler, not a replacer." AI and Quantum Technology : The firm has a specialized focus on the convergence of AI and quantum computing, particularly through investments like SandboxAQ (Google spin-out), Xaira (AI drug discovery, co-founded by Nobel laureate Dr. David Baker), and SandboxAQ. The firm seeks transformational rather than incremental investments at the frontier of computational science. Healthcare & Life Sciences (AI-driven) : Breyer Capital's most developed thesis pillar targets the intersection of scientific discovery, clinical necessity, and institutional transformation. The healthcare thesis is organized around three catalytic forces: (1) computation recasting medicine as an information science, (2) precision medicine aligning interventions with individual biology, and (3) prevention shifting care toward anticipatory risk systems. The firm aims to "rearchitect healthcare at its core" rather than optimize existing broken systems. Focus areas include AI-first diagnostics (Cleerly, OM1, Verana Health), programmable therapeutics (Xaira, Soley Therapeutics), biomedical development acceleration (PostEra, Form Bio), clinician empowerment software (Suki, Open Evidence), and new care delivery models (Harbor Health, Lyra Health). Consumer Software and Media/Gaming : Building on Jim's legendary track record in consumer internet — Facebook, Spotify, Headspace, Grammarly — the firm continues backing distinctive consumer experiences at the intersection of AI and engagement. This includes AI search (You.com), gaming (Epic Games, 100 Thieves, GOLF+, Niantic), and media (Legendary, 21st Century Fox, Marvel). FinTech : Active in fintech innovation spanning traditional payments and financial services (Stash, ZenBusiness, Circle) and frontier Web3/DeFi (Chia, EigenLayer, Parallel Finance, Jarsy). Ted Breyer co-founded Breyer Labs (crypto fund) and Atoka (crypto recovery), signaling deep internal commitment to this space. Enterprise & Data : Selective investments in enterprise software and data infrastructure with AI components (C3.ai, Pryon, data.world, AmplifAI, Slope). Security & Defense : Notable portfolio includes Shield AI (autonomous AI for defense and first responders), Mark43 (public safety), Wickr (encrypted communications, acquired by AWS), and Citizen (safety app). Climate : Growing commitment to climate tech (Pledge, Tenet, Charm Industrial, Colossal Biosciences for de-extinction/biotechnology, Heirloom for carbon removal). Stage Focus Breyer Capital invests across multiple stages, from pre-seed through growth equity. The firm is comfortable writing its first check at inception ("often at inception" per their own healthcare thesis language) and following on through later rounds. Recent examples span $5M pre-seed (Jarsy, June 2025) through $300M+ Series E (SandboxAQ, Dec 2024). This multi-stage flexibility reflects Breyer's approach as a long-term, partnership-oriented investor. Check Size Not publicly disclosed. Based on portfolio evidence: pre-seed investments appear to be in the $500K–$3M range; Series A–C participation likely $5–25M; growth equity rounds may be $25M+. The firm does not publish a standard check size target. Lead Tendency Jim Breyer typically takes a board seat and/or lead investor role in early-stage investments. The firm participates in later-stage rounds of existing portfolio companies as follow-on. Lead tendency is classified as "leads" for initial investments. Recent Activity (2024–2026) Breyer Capital has been active with approximately 10 investments per year. Recent transactions include: February 2026 : SiFi (Saudi fintech, expense management, Series A) September 2025 : Harbor Health ($225M+ growth round, primary/specialty care with integrated insurance) August 2025 : Hemi ($30M growth round, modular blockchain network) June 2025 : Jarsy (led $5M pre-seed, private equity tokenization platform) June 2025 : Circle (portfolio exit — IPO on NYSE at ~$6.22B market cap) April 2025 : Morgan Cheatham joins as Partner and Head of Healthcare from Bessemer VP January 2025 : Colossal Biosciences ($200M Series C, de-extinction/biotech) December 2024 : SandboxAQ (Series E, $300M+, AI/quantum) December 2024 : Cleerly ($106M Series C, cardiovascular AI imaging) October 2025 : Dynamic (portfolio exit — acquired) October 2024 : Suki ($70M Series D, AI healthcare assistant) December 2025 : Dr. Bret Bostwick joins as Venture Advisor Portfolio Highlights Notable Exits: Meta/Facebook — IPO, 100x+ return for Breyer Capital Spotify — IPO Etsy — IPO Circle — IPO on NYSE, June 2025, ~$6.22B market cap Meesho — IPO on BSE/NSE, December 2025, ~$5.57B market cap Marvel Entertainment — acquired by Disney Datalogix — acquired by Oracle Wickr — acquired by AWS Dynamic — acquired, October 2025 Active Portfolio (Selected): SandboxAQ, Shield AI, Grammarly, You.com (unicorn since 2025), Xaira, Lyra Health, Niantic, Epic Games, C3.ai, OpenEvidence, Headspace, Colossal Biosciences, Suki, Cleerly, Hemi Team Jim Breyer — Founder and CEO. Stanford AB; Harvard Business School (Baker Scholar). Former Managing Partner at Accel Partners (20+ years, 1987–2011). Early investor in 40+ companies with successful exits. Board member at Blackstone (since 2016). Harvard Corporation Fellow Emeritus. Stanford Engineering Venture Fund Chairman. Minority owner of Boston Celtics. Daniel Breyer — Partner. Brown University (magna cum laude, History). Leads consumer-focused investments: Headspace, Grammarly, Epic Games, Stash, Zepto, OnyxOdds. Co-founded Flare (portfolio company). Ted Breyer — Partner. Harvard University; Schwarzman Scholar, Tsinghua University. Leads fintech and crypto investing. Co-founded Breyer Labs (crypto fund) and Atoka (cryptocurrency recovery). Morgan Cheatham, MD — Partner and Head of Healthcare & Life Sciences (joined April 2025). B.S. Computational Decision Sciences; MD from Brown University. Formerly VP at Bessemer Venture Partners (sourced Abridge, Hinge Health). Forbes 30 Under 30 in VC (2023). Fellowship in Clinical Genetics at Harvard/Boston Children's; Editorial Associate at NEJM AI; Board member, Coalition for Health AI. Samuel J. Palmisano — Venture Advisor. Former Chairman, President and CEO of IBM (2003–2011). Chairman of Center for Global Enterprise. Bret Bostwick, MD, FAAP, FACMG — Venture Advisor (joined December 2025). Physician-scientist at Alnylam Pharmaceuticals. Former faculty at Baylor College of Medicine. Leo Grady — CEO in Residence. 18 years in ML/AI and digital health. Former CEO of Paige (AI pathology). Currently Founder & CEO of Jona Health. Geographic Focus Primarily United States with a base in Austin, TX and Menlo Park, CA. The firm also invests globally, with portfolio companies in India (Meesho, Zepto, Taager), Middle East (SiFi in Saudi Arabia, Huspy in UAE), Africa (mPharma, Wasoko, Tushop), and Europe/UK (Viva Wallet, Nesto, TapTap Send). Decision Process As a family office/VC hybrid, decision-making centers on Jim Breyer with a small partnership team. The firm operates as a partnership with Jim, Daniel Breyer, Ted Breyer, and Morgan Cheatham. Long-term orientation is emphasized; Jim Breyer often stays on boards through IPO. Academic Partnerships Since 2016, Breyer Capital has emphasized deep collaborations with leading universities including Stanford, Harvard, MIT, UCSF, and University of Texas at Austin, particularly in AI and life sciences. They partnered with Harvard Medical School's Department of Biomedical Informatics in 2025 to support AI-driven precision medicine.